Molecular Identification of Extended- Spectrum β-lactamase Genes in Klebsiella pneumoniae Strains by Multiplex PCR in Arak, Iran


1 M.Sc of Microbiology, Department of Microbiology, Qom Branch, Islamic Azad University, Qom, IRAN

2 Associate Professor of Microbiology, Department of Microbiology, Qom Branch, Islamic Azad University, Qom, IRAN

3 Assistant Professor of Microbiology, Department of Microbiology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran


Introduction: One of the enzymes that is produced by Gram negative bacteria is Extended spectrum-β-lactamases (ESBLs) which was first described in the 1980s. This study aims at identifying three common genes (blaTEM, blaSHV and blaCTX-M) in Klebsiella pneumoniae isolated from patients in Arak, Iran. Methods: A total number of 112 isolates were selected during 2012-2013. To identify phenotypic specifications, Combination Disk Method based on CLSI guidelines. The ESBL’s genotype was analyzed by multiplex PCR and DNA sequencing. Results: Among 10 examined antibiotics, the most resistant and susceptible antibiotics were ampicillin and imipenem, respectively. The phenotypic determination of ESBL showed that 46.42% of isolates produced ESBL. The molecular survey of genes showed that 35.89% had CTX-M, 5.12% had both CTX-M and TEM and 2.56% had TEM, SHV, CTX-M. Conclusion: According to the findings, the high prevalence (73.07%) of ESBL producing K. pneumoniae was observed with a new pattern of blaCTX-M distribution differed from other countries.


1. Bagley ST. Habitat association of Klebsiella species. Infect Control. 1985; 6: 52- 8.
2. Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8: 557- 584.
3. Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994; 13: 17- 29.
4. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichiacoli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother. 2008; 52: 2818- 2824.
5. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. And ESBL-producing Klebsiella spp: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents. 2003; 21: 1- 7.
6. Otman J, Perugini M, Tognim M, Vidotto M. Atypical phenotypic characteristics of klebsiella pneumoniae isolates from an outbreak in a neonatal intensive care unit in Brazil. Braz J Microbiol. 2007; 38: 273- 277.
7. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, Bonomo RA,and the International Klebsiella Study Group. Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. AntimicrobAgentsChemother. 2003; 47: 3554- 3560.
8. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18: 657- 686.
9. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents. 2000; 14: 137- 142.
10. Bonnet R, Dutour C, Sampaio JL, Chanal C, Sirot D, Labia R, De Champs C, Sirot J. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly. Antimicrob Agents Chemother. 2001; 45: 2269- 2275.
11. Kariuki S, Corkill JE, Revathi G, Musoke R, Hart CA. Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya. Antimicrob Agents Chemother. 2001; 45: 2141- 2143.
12. Oliver A, Perez-Diaz JC, Coque TM, Baquero F, Canton R. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-10) isolated in Spain. Antimicrob Agents Chemother. 2001; 45: 616- 620.
13. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004; 48: 1- 14.
14. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, Nordmann P. CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single
amino acid substitution in the omega loop. Antimicrob Agents Chemother. 2001; 45: 3355- 3361.
15. Lal P, Kapil A, Das BK, Sood S. Occurrence of TEM & SHV gene in extended spectrum beta-lactamases (ESBLs) producing Klebsiella sp. isolated from a tertiary care hospital. Indian J Med Res. 2007; 125: 173- 178.
16. Nijssen S, Florijn A, Bonten MJ, Schmitz FJ, Verhoef J, Fluit AC. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J AntimicrobAgents. 2004; 24: 585- 91.
17. Mendonca N, Ferreira E, Louro D, Canica M. Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in Portugal. Int J AntimicrobAgents. 2009; 34: 29- 37.
18. Gupta A, Ampofo K, Rubenstein D, Saiman L. Extended spectrum beta lactamase-producing Klebsiella pneumoniae infections: a review of the literature. J Perinatol. 2003; 23: 439- 443.
19. Lim KT, Yasin R, Yeo CC, Puthucheary S, Thong KL. Characterization of multidrug resistant ESBL-producing Escherichia coli isolates from hospitals in Malaysia. J biomed biotechnol. 2009; 2009: 165637.
20. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14: 933- 951.
21. Bali EB, Aç KL, Sultan N. Phenotypic and molecular characterization of SHV, TEM, and CTX-M and extended-spectrum β -lactamase produced by Escherichia coli, Acinobacter baumannii and Klebsiella isolates in a Turkish hospital. Afr J Microbiol Res. 2010; 4: 650- 654.
22. Myer K. Methods in biochemical identification of bacteria. Myer’s and Koshi’s manual of diagnostic procedures in medical microbiology and
immunology/serology, 2nd ed Vellore: Department of Clinical Microbiology, Christian Medical College. 2001: 195- 202.
23. Patel JB, Cockerill FR, Alder J, Bradford PA, Eliopoulos GM, Hardy DJ, et al. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. Clinical and Laboratory Standards Institute. 2014.
24. Ho PL, Chow KH, Yuen KY, Ng WS, Chau PY. Comparison of a novel, inhibitor-potentiated disc-diffusion test with other methods for the detection of extended-spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother. 1998; 42: 49- 54.
25. Marra AR, Pereira CA, Castelo A, do Carmo Filho JR, Cal RG, Sader HS, Wey SB. Health and economic outcomes of the detection of Klebsiell apneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection. Int J Infect Dis. 2006; 10: 56- 60.
26. Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol. 1998; 47: 201- 209.
27. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiella pneumoniae. Clin Infect Dis. 2001; 33: 1288- 1294.